Literature DB >> 28630119

GATA2 haploinsufficiency accelerates EVI1-driven leukemogenesis.

Saori Katayama1,2, Mikiko Suzuki3, Ayaka Yamaoka1, Nadine Keleku-Lukwete1, Fumiki Katsuoka4, Akihito Otsuki5, Shigeo Kure2, James Douglas Engel6, Masayuki Yamamoto1,6.   

Abstract

Chromosomal rearrangements between 3q21 and 3q26 induce inappropriate EVI1 expression by recruiting a GATA2-distal hematopoietic enhancer (G2DHE) to the proximity of the EVI1 gene, leading to myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The acquisition of G2DHE by the EVI1 gene reciprocally deprives this enhancer of 1 of the 2 GATA2 alleles, resulting in a loss-of-function genetic reduction in GATA2 abundance. Because GATA2 haploinsufficiency is strongly associated with MDS and AML, we asked whether EVI1 misexpression and GATA2 haploinsufficiency both contributed to the observed leukemogenesis by using a 3q21q26 mouse model that recapitulates the G2DHE-driven EVI1 misexpression, but in this case, it was coupled to a Gata2 heterozygous germ line deletion. Of note, the Gata2 heterozygous deletion promoted the EVI1-provoked leukemic transformation, resulting in early onset of leukemia. The 3q21q26 mice suffered from leukemia in which B220+ cells and/or Gr1+ leukemic cells occupied their bone marrows. We found that the B220+Gr1-c-Kit+ population contained leukemia-initiating cells and supplied Gr1+ leukemia cells in the 3q21q26 leukemia. When Gata2 expression levels in the B220+Gr1-c-Kit+ cells were decreased as a result of Gata2 heterozygous deletion or spontaneous phenomenon, myeloid differentiation of the B220+Gr1-c-Kit+ cells was suppressed, and the cells acquired induced proliferation as well as B-lymphoid-primed characteristics. Competitive transplantation analysis revealed that Gata2 heterozygous deletion confers selective advantage to EVI1-expressing leukemia cell expansion in recipient mice. These results demonstrate that both the inappropriate stimulation of EVI1 and the loss of 1 allele equivalent of Gata2 expression contribute to the acceleration of leukemogenesis.
© 2017 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28630119     DOI: 10.1182/blood-2016-12-756767

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

Review 1.  Blood disease-causing and -suppressing transcriptional enhancers: general principles and GATA2 mechanisms.

Authors:  Emery H Bresnick; Kirby D Johnson
Journal:  Blood Adv       Date:  2019-07-09

Review 2.  Gene expression at a single-molecule level: implications for myelodysplastic syndromes and acute myeloid leukemia.

Authors:  Justin C Wheat; Ulrich Steidl
Journal:  Blood       Date:  2021-08-26       Impact factor: 25.476

Review 3.  Enhancer dysfunction in leukemia.

Authors:  Anand S Bhagwat; Bin Lu; Christopher R Vakoc
Journal:  Blood       Date:  2018-02-09       Impact factor: 25.476

4.  Aberrant GATA2 Activation in Pediatric B-Cell Acute Lymphoblastic Leukemia.

Authors:  Han Wang; Bowen Cui; Huiying Sun; Fang Zhang; Jianan Rao; Ronghua Wang; Shuang Zhao; Shuhong Shen; Yu Liu
Journal:  Front Pediatr       Date:  2022-01-11       Impact factor: 3.418

5.  Identification of therapeutic targets of the hijacked super-enhancer complex in EVI1-rearranged leukemia.

Authors:  Sandra Kiehlmeier; Mahmoud-Reza Rafiee; Ali Bakr; Jagoda Mika; Sabrina Kruse; Judith Müller; Sabrina Schweiggert; Carl Herrmann; Gianluca Sigismondo; Peter Schmezer; Jeroen Krijgsveld; Stefan Gröschel
Journal:  Leukemia       Date:  2021-04-28       Impact factor: 12.883

6.  EVI1 and GATA2 misexpression induced by inv(3)(q21q26) contribute to megakaryocyte-lineage skewing and leukemogenesis.

Authors:  Ayaka Yamaoka; Mikiko Suzuki; Saori Katayama; Daiki Orihara; James Douglas Engel; Masayuki Yamamoto
Journal:  Blood Adv       Date:  2020-04-28

7.  Tumor suppressor function of Gata2 in acute promyelocytic leukemia.

Authors:  Casey D S Katerndahl; Olivia R S Rogers; Ryan B Day; Michelle A Cai; Timothy P Rooney; Nichole M Helton; Mieke Hoock; Sai Mukund Ramakrishnan; Sridhar Nonavinkere Srivatsan; Lukas D Wartman; Christopher A Miller; Timothy J Ley
Journal:  Blood       Date:  2021-09-30       Impact factor: 25.476

8.  Gata2 as a Crucial Regulator of Stem Cells in Adult Hematopoiesis and Acute Myeloid Leukemia.

Authors:  Juan Bautista Menendez-Gonzalez; Milica Vukovic; Ali Abdelfattah; Lubaid Saleh; Alhomidi Almotiri; Leigh-Anne Thomas; Aloña Agirre-Lizaso; Aleksandra Azevedo; Ana Catarina Menezes; Giusy Tornillo; Sarah Edkins; Kay Kong; Peter Giles; Fernando Anjos-Afonso; Alex Tonks; Ashleigh S Boyd; Kamil R Kranc; Neil P Rodrigues
Journal:  Stem Cell Reports       Date:  2019-08-01       Impact factor: 7.765

9.  Constructing and deconstructing GATA2-regulated cell fate programs to establish developmental trajectories.

Authors:  Kirby D Johnson; Daniel J Conn; Evgenia Shishkova; Koichi R Katsumura; Peng Liu; Siqi Shen; Erik A Ranheim; Sean G Kraus; Weixin Wang; Katherine R Calvo; Amy P Hsu; Steven M Holland; Joshua J Coon; Sunduz Keles; Emery H Bresnick
Journal:  J Exp Med       Date:  2020-11-02       Impact factor: 14.307

10.  Intra-heterogeneity in transcription and chemoresistant property of leukemia-initiating cells in murine Setd2-/- acute myeloid leukemia.

Authors:  Jiachun Song; Longting Du; Ping Liu; Fuhui Wang; Bo Zhang; Yinyin Xie; Jing Lu; Yi Jin; Yan Zhou; Gang Lv; Jianmin Zhang; Saijuan Chen; Zhu Chen; Xiaojian Sun; Yuanliang Zhang; Qiuhua Huang
Journal:  Cancer Commun (Lond)       Date:  2021-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.